1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
BUSINESS
Shift to Specialty – 3: Meiji Seika Pharma to Focus Pipeline, Optimize Sales Force
Meiji Seika Pharma bills itself as a “specialty and generic pharmaceuticals company” with a unique business model, which includes generics as well as original drugs in the fields of infectious and CNS diseases. What impact will the company’s policy to…
To read the full story
Related Article
- Shift to Specialty - 5: Eisai, Ajinomoto Jump on Specialty Bandwagon to Seek Efficiency in GI Biz
October 30, 2015
- Shift to Specialty - 4: Ceolia Pharma Aims to Be Single-Source Provider in Field of ENT
October 28, 2015
- Shift to Specialty – 2: Santen Invests in the Future Over Present Profits
October 21, 2015
- Shift to Specialty - 1: Drug Makers Urged to Retool Strategies amid Govt Pressure, Dismal Biz Environment
October 19, 2015
BUSINESS
- Some Generics See Lower Profit Margins, Return to LLPs after Elective Care Rollout
February 28, 2025
- FRONTEO to Provide AI-Based Drug Discovery Support Service in US
February 28, 2025
- AstraZeneca Rolling Out “Unify” App for Decentralized Trials in Japan
February 27, 2025
- Daiichi Eyes 9 New Indications for 2 Lead ADCs, Tripling Patient Number by 2026
February 27, 2025
- Kissei Files Linzagolix for Uterine Fibroids in Japan
February 27, 2025
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…